Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study.

Yu D, Zou M, Pan Q, Song Y, Li M, Zhang X, Zhou Y, Wang X, Guo L

Frontiers in endocrinology26 Aug 2022Cited by 17 (Europe PMC)

PMID36093105PMCIDPMC9458907DOI10.3389/fendo.2022.951570PepBankPUB-36093105

Summary

ObjectiveTo study the effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on glucose metabolism and abdominal fat distribution in patients with obesity and type 2 diabetes mellitus (T2DM).MethodsFrom April 30, 2020, to April 30, 2022, a prospective randomized controlled study was carried out at the Endocrinology Department of Beijing Hospital, the National Center of Gerontology. According to the in- and exclusion criteria and by the random table method, revisited T2DM patients were selected as the research subjects and were allocated into a Study group (taking liraglutide) and a Control group (underwent lifestyle interventions). All patients received continuous 12-weeks interventions to the endpoint, and the changes of value [Δ=(endpoint)-(baseline)] of physical measurements, blood tests, the energy spectrum CT examination results, and body composition analysis results were analyzed and compared.ResultsA total of 85 people completed this study, and among them, 47 were in the Study group and 38 were in the Control group. Compared with the Control group, the changes of hemoglobin A1c (HbA1c) level (-0.78 ± 1.03% vs. -1.57 ± 2.00%, P=0.025), visceral fat area (0.91 ± 16.59 cm² vs. -7.1 ± 10.17 cm², P=0.011), and subcutaneous fat area of abdomen [0 (-18.75, 15.5) cm² vs. -16.5 (-41.75, -2.25) cm², P=0.014] were all greater in the Study group. The adverse events caused by liraglutide were mainly concentrated in the gastrointestinal system and all of them were minor adverse events.ConclusionLiraglutide can be the drug of choice for weight management and reduction of abdominal fat distribution in patients with obesity and T2DM.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In people with obesity and type 2 diabetes, liraglutide lowered HbA1c more than lifestyle intervention over 12 weeks (-1.57% vs -0.78%; P = 0.025).
In plain wordsIn people with obesity and type 2 diabetes, liraglutide lowered HbA1c more than lifestyle changes alone.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at 12 weeks
Study
n = 85
Comparator
Lifestyle intervention
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
HbA1c change
−1.57%
liraglutide group
HbA1c change
−0.78%
lifestyle group
Source sentences
Summary
the changes of hemoglobin A1c (HbA1c) level (-0.78 ± 1.03% vs. -1.57 ± 2.00%, P=0.025)
3 context sentences(design, population, supporting numbers)
Summary · context
were all greater in the Study group.
Summary · context
According to the in- and exclusion criteria and by the random table method, revisited T2DM patients were selected as the research subjects and were allocated into a Study group (taking liraglutide) and a Control group (underwent lifestyle interventions).
Summary · context
All patients received continuous 12-weeks interventions to the endpoint, and the changes of value [Δ=(endpoint)-(baseline)] of physical measurements, blood tests, the energy spectrum CT examination results, and body composition analysis results were analyzed and compared.
Show in the study text Report a problemFND-3609310501
02HumanRandomized controlled trialEfficacy outcome
In people with obesity and type 2 diabetes, liraglutide reduced visceral fat area more than lifestyle intervention over 12 weeks (-7.1 vs 0.91 cm2; P = 0.011).
In plain wordsIn people with obesity and type 2 diabetes, liraglutide reduced belly organ fat more than lifestyle changes alone.
Peptide
Liraglutide
Outcome
DecreaseVisceral fat area change at 12 weeks
Study
n = 85
Comparator
Lifestyle intervention
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Visceral fat area change
−7.1 cm2
liraglutide group
Visceral fat area change
0.91 cm2
lifestyle group
Source sentences
Summary
visceral fat area (0.91 ± 16.59 cm² vs. -7.1 ± 10.17 cm², P=0.011)
3 context sentences(design, population, supporting numbers)
Summary · context
were all greater in the Study group.
Summary · context
According to the in- and exclusion criteria and by the random table method, revisited T2DM patients were selected as the research subjects and were allocated into a Study group (taking liraglutide) and a Control group (underwent lifestyle interventions).
Summary · context
All patients received continuous 12-weeks interventions to the endpoint, and the changes of value [Δ=(endpoint)-(baseline)] of physical measurements, blood tests, the energy spectrum CT examination results, and body composition analysis results were analyzed and compared.
Show in the study text Report a problemFND-3609310502
03HumanRandomized controlled trialEfficacy outcome
In people with obesity and type 2 diabetes, liraglutide reduced abdominal subcutaneous fat area more than lifestyle intervention over 12 weeks (P = 0.014).
In plain wordsIn people with obesity and type 2 diabetes, liraglutide reduced fat under the belly skin more than lifestyle changes alone.
Peptide
Liraglutide
Outcome
DecreaseAbdominal subcutaneous fat area change at 12 weeks
Study
n = 85
Comparator
Lifestyle intervention
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
subcutaneous fat area of abdomen [0 (-18.75, 15.5) cm² vs. -16.5 (-41.75, -2.25) cm², P=0.014]
3 context sentences(design, population, supporting numbers)
Summary · context
were all greater in the Study group.
Summary · context
According to the in- and exclusion criteria and by the random table method, revisited T2DM patients were selected as the research subjects and were allocated into a Study group (taking liraglutide) and a Control group (underwent lifestyle interventions).
Summary · context
All patients received continuous 12-weeks interventions to the endpoint, and the changes of value [Δ=(endpoint)-(baseline)] of physical measurements, blood tests, the energy spectrum CT examination results, and body composition analysis results were analyzed and compared.
Show in the study text Report a problemFND-3609310503
04HumanRandomized controlled trialSafety outcome
In people with obesity and type 2 diabetes, adverse events caused by liraglutide were mainly gastrointestinal and all were minor.
In plain wordsIn people with obesity and type 2 diabetes, side effects of liraglutide were mostly stomach and gut problems, and all were minor.
Peptide
Liraglutide
Outcome
Not applicableAdverse events with liraglutide
Study
n = 47
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
The adverse events caused by liraglutide were mainly concentrated in the gastrointestinal system and all of them were minor adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
According to the in- and exclusion criteria and by the random table method, revisited T2DM patients were selected as the research subjects and were allocated into a Study group (taking liraglutide) and a Control group (underwent lifestyle interventions).
Summary · context
All patients received continuous 12-weeks interventions to the endpoint, and the changes of value [Δ=(endpoint)-(baseline)] of physical measurements, blood tests, the energy spectrum CT examination results, and body composition analysis results were analyzed and compared.
Show in the study text Report a problemFND-3609310504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.